Dr. Steven Tersigni First Refractive Surgeon in Oregon to Implant New Lens

Lake Oswego, Oregon -

In a significant leap forward for vision correction and the medical industry at large, Tersigni Vision is proud to announce a remarkable achievement. Dr. Steven Tersigni, the clinic's renowned founder, has distinguished himself as the first refractive surgeon in Oregon to implant the IC-8® Apthera™ Intraocular Lens (IOL). This surgical feat not only underscores Oregon's place on the world stage of advanced ophthalmic treatments but also further solidifies Tersigni Vision's reputation as a pioneer in vision correction technology.

A crucial medical device company, AcuFocus, Inc., earned FDA approval for its ground-breaking IC-8 Apthera IOL. This lens, an industry-first, harnesses proprietary small aperture technology to filter out peripheral defocused light, allowing only focused light to reach the retina. Tersigni Vision is leading the charge in integrating this transformative technology into its practice, promising patients a fresh, unparalleled level of vision correction.

The landmark first successful implantation of the Apthera IOL by Dr. Tersigni signals a significant evolution in the treatment of cataracts—a prevalent issue projected to affect nearly 50 million people in the U.S. by 2050, a significant jump from today's 24.4 million. The introduction of this cutting-edge lens provides an effective, forward-looking solution to this rising health concern, making this achievement all the more noteworthy.

According to the U.S. pivotal trial data, subjects with the Apthera IOL demonstrated statistically superior uncorrected intermediate and near vision, along with equivalent distance vision and contrast sensitivity, compared to control subjects. This is an immense advancement for the estimated 82% of cataract patients who have up to 1.5 diopters of corneal astigmatism, providing them with an unparalleled vision correction option.

"The integration of this pioneering technology into our surgical procedures represents a tremendous leap in vision correction," Dr. Tersigni stated. "As the first surgeon in Oregon to utilize the IC-8 Apthera IOL, I am overjoyed to offer our patients an effective solution that enhances both their distance and near vision. At Tersigni Vision, we are devoted to remaining at the forefront of innovation, providing our patients with the highest level of eye care, and the IC-8 Apthera IOL aligns perfectly with this vision."

The IC-8 Apthera IOL sets itself apart from other lens designs with its small aperture technology, offering patients a continuous range of vision from far through intermediate to near. It also uniquely serves patients with up to 1.5 D of corneal astigmatism, effectively eliminating the negative effects of presbyopia. This breakthrough technology is a true game-changer in the field of refractive surgery, assuring a broadened range of visual acuity while simplifying the complex field of presbyopia-correcting lens designs.

With the successful introduction of the IC-8 Apthera IOL in Oregon, Tersigni Vision extends a warm invitation to industry professionals and prospective patients to delve deeper into this innovative technology and its considerable benefits. As part of this commitment, Dr. Tersigni is offering his expertise to those interested and is available for interviews and discussions about the IC-8 Apthera IOL and his groundbreaking first implantation procedure in Oregon.

Additionally, Tersigni Vision is also eager to participate in research and development activities that further the understanding and application of the IC-8 Apthera IOL. Dr. Tersigni is steadfast in his resolve to continually advance the field of ophthalmic surgery and is always looking to partner with organizations that share the same objective.

"Without a doubt, the IC-8 Apthera IOL represents a significant advancement in our ongoing efforts to provide optimal patient outcomes," Dr. Tersigni added. "As we continue to learn more about this innovative lens and its benefits, we look forward to providing patients with even greater vision correction options. Together with our skilled team and our commitment to using state-of-the-art technology, Tersigni Vision will continue to transform lives and make a significant impact in our community."

Interested parties are encouraged to learn more about the IC-8 Apthera Intraocular Lens, its benefits, and Dr. Tersigni's pivotal role in this significant medical advancement.

About Tersigni Vision

Tersigni Vision, led by the pioneering refractive surgeon Dr. Steven Tersigni, is Oregon's leading vision correction clinic. Committed to delivering the most advanced ophthalmic treatments and providing personalized patient care, Tersigni Vision continues to innovate in the field of refractive surgery. The clinic offers a wide range of services, including cataract surgery and advanced lens implantation, helping patients achieve superior vision and a heightened quality of life. For further information, visit www.tersignivision.com.